Showing 751-760 of 1556 results for "".
- New from Jergens: Nourishing Honey Dry Skin Moisturizerhttps://practicaldermatology.com/news/new-from-jergens-nourishing-honey-dry-skin-moisturizer/2457984/Jergens is launching their new Nourishing Honey Dry Skin Moisturizer. Formulated with antioxidant-packed Orange Blossom Honey, which is known to contain potent antibacterial and anti-inflammatory properties, the new Jergens® Nouri
- Is a Topical Gel Made From Oral Blood Pressure Drugs a Panacea for Wound Healing, Wrinkles and More?https://practicaldermatology.com/news/is-a-topical-gel-made-from-oral-blood-pressure-drugs-a-panacea-for-wound-healing-wrinkles-and-more/2457989/Topical gel made from angiotensin II receptor blockers may speed the healing of chronic skin wounds in mice and pigs, Johns Hopkins researchers report. The findings, published in the Journal of Investigative Dermatology, marks efforts to seek approval from the U.S. Food and Drug
- The Prescription Dermatological Drugs Market Forecasthttps://practicaldermatology.com/news/the-prescription-dermatological-drugs-market-forecast/2458079/The "World Prescription Dermatological Drugs Market, 10th Edition" report, now available from Research and Markets shows the field
- Pfizer Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for XELJANZ® (tofacitinib citrate) for the Treatment of Adult Patients with Active Psoriatic Arthritishttps://practicaldermatology.com/news/pfizer-announces-us-fda-filing-acceptance-of-supplemental-new-drug-application-for-xeljanz-tofacitinib-citrate-for-the-treatment-of-adult-patients-wit/2458195/(via BusinessWire) Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) has accepted for rev
- Merz Aesthetics Launches Mederma Quick Dry Oil, Mederma Spezialhttps://practicaldermatology.com/news/merz-aesthetics-launces-mederma-quick-dry-oil-mederma-spezial/2458210/Merz Aesthetics is officially launching Mederma Quick Dry Oil and Mederma Spezial in the US. Mederma Quick Dry Oil contains a complex blend of oils, botanicals and pa
- Allergan and Paratek Pharmaceuticals' Acne Drug Performs Well in Phase 3 Trialshttps://practicaldermatology.com/news/allergan-and-paratek-pharmaceuticals-acne-drug-performs-well-in-phase-3-trials/2458234/Allergan and Paratek Pharmaceuticals, Inc.’s investigational acne drug performed well in two Phase 3 studies, the companies report. Sarecycline, a once-daily, oral, narrow spectrum tetracycline-derived anti
- Mosquito Virus Expert Discusses a Promising New Drug For Zikahttps://practicaldermatology.com/news/mosquito-virus-expert-discusses-a-promising-new-drug-for-zika/2458257/Thomas Voss, PhD, a world-renowned leader in infectious disease research, and his team, say there are two strategies for developing a defense program against Zika infection: prevention, achieved by developing an effective vaccine and vaccination program or the development of a drug that can kill
- Realm Therapeutics Submits Investigational New Drug Application for PR022 for Atopic Dermatitishttps://practicaldermatology.com/news/realm-therapeutics-submits-investigational-new-drug-application-for-pr022-for-atopic-dermatitis/2458305/Realm Therapeutics plc submitted its first investigational new drug (IND) application to the FDA for PR022 as a novel treatment for atopic dermatitis (AD). Pending acceptance, the IND will enable Realm to initiate a Phase 2a proof-of-concept trial for patients with atopic dermatitis.
- Beauty Drinks Poised to Be Cosmeceutical Industry's Next Billion-Dollar Babyhttps://practicaldermatology.com/news/beauty-drinks-poised-to-be-cosmeceutical-industrys-next-billion-dollar-baby/2458361/Beauty drinks are everywhere today, and many youth seekers turning to them as a way to improve skin and get their glow on from the inside out. In fact, beauty drinks are slated to become a billion dollar market, according to a new
- Orphan Drug Designation Granted to Nintedanib for Systemic Sclerosishttps://practicaldermatology.com/news/orphan-drug-designation-granted-to-nintedanib-for-systemic-sclerosis/2458441/The European Commission (EC) and the FDA have granted Orphan Drug Designation to Boehringer Ingelheim's nintedanib for the treatment of systemic sclerosis (SSc, also known as scleroderma), including the associated interstitial lung disease (SSc-ILD).